SLC3A2 and breast carcinoma: Further analysis of Cox regression in the subgroup of patients who were treated with endocrine therapy alone revealed that SLC7A5+SLC3A2+ co-expression at both the mRNA and protein levels is a predictive marker for a high risk of disease recurrence, distant metastasis and breast cancer death (p < 0.05; Table 4).